CataloniaBio & HealthTech has presented the Bioèxit 2023 Award to SpliceBio and Avinent Implant System for the milestones achieved during 2022 in the field of health and life sciences in Catalonia. The award ceremony was held as part of the CataloniaBio & HealthTech Gala at CaixaForum Barcelona, with more than 340 attendees, including authorities from international, state and Catalan public administrations, and members of the association among entrepreneurs, executives and investors in the sector.
This year the jury decided to award the Bioèxit prize to two companies, "as an indicator of the progress in the sector's maturity in innovation and in the structure of the business ecosystem". This was explained by Mariona Serra, vice-president of CataloniaBio & HealthTech, during the presentation of the award.
In the case of SpliceBio, the jury particularly valued its capacity to attract international and national funds. In 2022, the biotech raised a €50M Series A, the largest for a biotech company in Catalonia and Spain to date, which will allow them to continue developing their gene therapy programmes for the treatment of rare diseases. The round had the participation of a strong international syndicate including New Enterprise Associates (USA), Novartis Venture Fund (Switzerland), Gilde Healthcare (Netherlands) and Asabys (Spain). Due to the quality of the participating investors, SpliceBio's milestone is also a milestone for the sector, as it opens a door to the knowledge of the Catalan business network.
SpliceBio is a biotech spinout company from Princeton University (USA), which the founding team decided to found and set up in Barcelona. Miquel Vila i Perelló, CEO, received the award on behalf of the entire team.
Avinent Implant Systems has also been recognised with the Bioèxit 2023 award. In 2022, the company opened a new corporate headquarters. With an investment of more than 10 million euros, Avinent Hub is configured with large spaces that encourage inspiration, creativity and research, while allowing the development of new projects; making the most advanced technology and the most innovative processes available to the health sector. In this sense, in 2022 Avinent launched two new lines of business, which are incorporated into the existing ones: Avinent Orthodontics, in the dental sector, and Avinent Insoles, which represents the entry into the podiatry sector.
The Avinent Group closed the 2022 financial year with a turnover of more than 35 million euros, a presence in more than 26 countries and a team of more than 300 people. Albert Giralt, CEO of the company, received the award.
To date, the Bioèxit Award has been awarded to Oryzon (2015), Minoryx Therapeutics and Palobiofarma (2016), STAT-Dx and Mosaic Biomedicals (2017), Anaconda Biomed and Mind the Byte (2018), Ysios Capital and Antonio Parente (2019), Kymos (2020), ONA Therapeutics (2021) and IMIDomics (2022).
The CataloniaBio & HealthTech Night was supported by BCN Peptides (Gold Sponsor) and Genesis Biomed (Silver Sponsor), and with the collaboration of ACCIÓ.
You may also be interested in:
Comments